Exhibit 5.2
![LOGO](https://capedge.com/proxy/F-4/0001193125-22-253924/g407647dsp216.jpg)
D: +44 20 7614 2284
jho@cgsh.com
29 September 2022
Haleon plc
Building 5, First Floor
The Heights
Weybridge, Surrey, KT13 0NY
United Kingdom
GSK Consumer Healthcare Capital US LLC
184 Liberty Corner Road, Suite 200
Warren, NJ 07059
United States
GSK Consumer Healthcare Capital UK plc
Building 5, First Floor
The Heights
Weybridge, Surrey, KT13 0NY
United Kingdom
Ladies and Gentlemen:
We have acted as special English counsel to GSK Consumer Healthcare Capital UK plc, a public limited company incorporated in England and Wales (the “UK Issuer”), GSK Consumer Healthcare Capital US LLC, a Delaware limited liability company (the “US Issuer” and together with the UK Issuer, the “Issuers” and each an “Issuer”) and Haleon plc, a public limited company incorporated in England and Wales (the “Guarantor” and together with the UK Issuer, the “Companies” and each a “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), of a registration statement on Form F-4 (such registration statement, including the documents incorporated by reference therein but excluding Exhibit 25, hereinafter referred to as the “Registration Statement”) relating to the Issuers’ proposed offers to exchange (the “Exchange Offers”) (i) debt securities of the US Issuer consisting of $700,000,000 aggregate principal amount of 3.024% Callable Fixed Rate Senior Notes due 2024 and $300,000,000 aggregate principal amount of Callable Floating Rate Senior Notes due 2024 (together, the “2024 Notes”), $2,000,000,000 aggregate principal amount of 3.375% Fixed Rate Senior Notes due 2027 (the “2027 Notes”), $1,000,000,000 aggregate principal amount of 3.375% Fixed Rate
![LOGO](https://capedge.com/proxy/F-4/0001193125-22-253924/g407647dsp116a.jpg)